197 related articles for article (PubMed ID: 27334856)
1. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
Malkan UY; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
[TBL] [Abstract][Full Text] [Related]
4. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
Yu L; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
[No Abstract] [Full Text] [Related]
5. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
6. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Nishiyama-Fujita Y; Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto K; Fujita H; Fujioka I; Tsuchiya S; Kimura Y; Iwanaga E; Komatsu N; Asou N; Kizaki M; Hatta Y; Kawaguchi T
Ann Med; 2022 Dec; 54(1):1244-1254. PubMed ID: 35486442
[TBL] [Abstract][Full Text] [Related]
8. Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
R C; Malik PS; Sahoo RK; Sharawat S; Singh M; Garg V; Bhatia K; Kantak A; Kumar S; Kumar L
Ann Hematol; 2023 Aug; 102(8):2087-2096. PubMed ID: 37322094
[TBL] [Abstract][Full Text] [Related]
9. [Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].
Zhao HF; Zhang Y; Hu JY; Li Z; Zhou J; Yu FK; Zu YL; Zhou H; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):209-214. PubMed ID: 30929388
[No Abstract] [Full Text] [Related]
10. Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Pokorny R; Stenehjem DD; Gilreath JA
J Oncol Pharm Pract; 2022 Jun; 28(4):916-923. PubMed ID: 35132891
[TBL] [Abstract][Full Text] [Related]
11. Transplantation in CML in the TKI era: who, when, and how?
Niederwieser C; Kröger N
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):114-122. PubMed ID: 36485123
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
Nevejan L; Labarque V; Boeckx N
Eur J Haematol; 2024 Mar; 112(3):458-465. PubMed ID: 37985225
[TBL] [Abstract][Full Text] [Related]
13. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.
Hochhaus A; Breccia M; Saglio G; García-Gutiérrez V; Réa D; Janssen J; Apperley J
Leukemia; 2020 Jun; 34(6):1495-1502. PubMed ID: 32366938
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Chitanava T; Matvienko I; Shuvaev V; Voloshin S; Martynkevich I; Vlasova Y; Efremova E; Mileeva E; Pirkhalo A; Makarova T; Vlasik R; Karyagina E; Il Ina N; Medvedeva N; Dorofeeva N; Shneider T; Siordiya N; Kulemina O; Sbityakova E; Lazorko N; Alexeeva J; Motorin D; Morozova E; Lomaia E
Front Oncol; 2023; 13():1138683. PubMed ID: 37007128
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Collins JB; Muluneh B; Profitt S
J Oncol Pharm Pract; 2024 Mar; 30(2):385-396. PubMed ID: 38105466
[TBL] [Abstract][Full Text] [Related]
17. Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
Roy Moulik N; Keerthivasagam S; Pandey A; Agiwale J; Hegde K; Chatterjee G; Dhamne C; Prasad M; Chichra A; Srinivasan S; Mohanty P; Jain H; Shetty D; Tembhare P; Patkar N; Narula G; Subramanian PG; Banavali S
Br J Haematol; 2024 Apr; 204(4):1249-1261. PubMed ID: 38098201
[TBL] [Abstract][Full Text] [Related]
18. B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.
Yohannan B; George B
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233138
[TBL] [Abstract][Full Text] [Related]
19. [Recent findings and advances in treatment of chronic myeloid leukemia].
Takaku T
Rinsho Ketsueki; 2024; 65(5):385-389. PubMed ID: 38825517
[TBL] [Abstract][Full Text] [Related]
20. TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
Hochhaus A; Ernst T
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):106-112. PubMed ID: 34889388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
